Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 697

1.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2018 Dec 15. pii: jrheum.180478. doi: 10.3899/jrheum.180478. [Epub ahead of print]

PMID:
30554156
2.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Callis Duffin K, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2018 Dec 15. pii: jrheum.181077. doi: 10.3899/jrheum.181077. [Epub ahead of print]

PMID:
30554154
3.

Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls.

Polachek A, Polachek Shlomi I, Spitzer K, Pereira D, Ye JY, Chandran V, Laskin CA, Gladman DD.

Clin Rheumatol. 2018 Dec 7. doi: 10.1007/s10067-018-4385-7. [Epub ahead of print]

PMID:
30535992
4.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

5.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2018 Dec 8:961203318817132. doi: 10.1177/0961203318817132. [Epub ahead of print]

PMID:
30526328
6.

What Is Axial Psoriatic Arthritis?

Feld J, Chandran V, Gladman DD.

J Rheumatol. 2018 Dec;45(12):1611-1613. doi: 10.3899/jrheum.180802. No abstract available.

PMID:
30504477
7.

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2018 Nov 30. doi: 10.1002/acr.23789. [Epub ahead of print]

PMID:
30499259
8.

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2018 Nov 30. doi: 10.1002/art.40726. [Epub ahead of print]

PMID:
30499246
9.

Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience.

Tselios K, Yap KS, Pakchotanon R, Polachek A, Su J, Urowitz MB, Gladman DD.

Clin Rheumatol. 2018 Nov 14. doi: 10.1007/s10067-018-4363-0. [Epub ahead of print]

PMID:
30430267
10.

How can we define low disease activity in systemic lupus erythematosus?

Tselios K, Gladman DD, Urowitz MB.

Semin Arthritis Rheum. 2018 Oct 16. pii: S0049-0172(18)30485-2. doi: 10.1016/j.semarthrit.2018.10.013. [Epub ahead of print]

PMID:
30415943
11.

Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.

Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L.

J Rheumatol. 2018 Nov 1. pii: jrheum.180195. doi: 10.3899/jrheum.180195. [Epub ahead of print]

PMID:
30385708
12.

Psychosis in Systemic Lupus Erythematosus.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Sam Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2018 Oct 30. doi: 10.1002/art.40764. [Epub ahead of print]

PMID:
30375754
13.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

PMID:
30360969
14.

Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?

Tselios K, Deeb M, Gladman DD, Harvey P, Akhtari S, Mak S, Butany J, Urowitz MB.

J Rheumatol. 2018 Oct 15. pii: jrheum.180124. doi: 10.3899/jrheum.180124. [Epub ahead of print]

PMID:
30323009
15.

Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Nat Commun. 2018 Oct 9;9(1):4178. doi: 10.1038/s41467-018-06672-6.

16.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

17.

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.

Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N.

J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

18.

Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: A population-based study.

Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R, Paterson JM, Cheng SY, Jabbari S, Campbell W, Bernatsky S, Gladman DD, Tu K.

Arthritis Care Res (Hoboken). 2018 Sep 1. doi: 10.1002/acr.23743. [Epub ahead of print]

PMID:
30171803
19.

Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.

Yap KS, Ye JY, Li S, Gladman DD, Chandran V.

Ann Rheum Dis. 2018 Nov;77(11):1573-1577. doi: 10.1136/annrheumdis-2018-213334. Epub 2018 Aug 4.

PMID:
30077991
20.

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2018 Aug 1. pii: jrheum.171436. doi: 10.3899/jrheum.171436. [Epub ahead of print]

PMID:
30068764
21.

Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.

Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, Peschken C, Urowitz MB.

J Rheumatol. 2018 Oct;45(10):1440-1447. doi: 10.3899/jrheum.171307. Epub 2018 Aug 1.

22.

The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis.

Zhou W, Chandran V, Cook R, Gladman DD, Eder L.

Semin Arthritis Rheum. 2018 Jun 19. pii: S0049-0172(18)30152-5. doi: 10.1016/j.semarthrit.2018.06.001. [Epub ahead of print]

PMID:
30057322
23.

Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
24.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

PMID:
30044551
25.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.

RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

26.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

27.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19. Review.

PMID:
29928910
28.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Aug;45(9):1256-1262. doi: 10.3899/jrheum.171183. Epub 2018 Jun 15.

PMID:
29907666
29.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
30.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
31.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
32.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
33.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
34.

Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row?

Chandran V, Stecher L, Farewell V, Gladman DD.

Semin Arthritis Rheum. 2018 Mar 9. pii: S0049-0172(17)30705-9. doi: 10.1016/j.semarthrit.2018.03.002. [Epub ahead of print]

PMID:
29724452
35.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
36.

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Tselios K, Gladman DD, Harvey P, Su J, Urowitz MB.

Lupus. 2018 Aug;27(9):1415-1423. doi: 10.1177/0961203318770526. Epub 2018 Apr 17.

PMID:
29665757
37.

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Jul;27(8):1296-1302. doi: 10.1177/0961203318770018. Epub 2018 Apr 11.

PMID:
29642752
38.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

39.

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD.

J Rheumatol. 2018 Mar;45(3):378-384. doi: 10.3899/jrheum.170379. Epub 2018 Feb 1.

PMID:
29419462
40.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

PMID:
29361147
41.

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Touma Z, Gladman DD.

Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. eCollection 2017. Review.

42.

Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre YS, Clarke AE.

J Rheumatol. 2018 Mar;45(3):393-396. doi: 10.3899/jrheum.170652. Epub 2018 Jan 15.

PMID:
29335347
43.

Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1478-1487. doi: 10.1002/acr.23509. Epub 2018 Sep 1.

PMID:
29316357
44.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.

J Rheumatol. 2018 Mar;45(3):367-377. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15. Erratum in: J Rheumatol. 2018 Nov;45(11):1608.

45.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

46.

Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia.

AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD.

J Rheumatol. 2018 Feb;45(2):213-217. doi: 10.3899/jrheum.170384. Epub 2017 Dec 1.

PMID:
29196385
47.

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1294-1302. doi: 10.1002/acr.23480. Epub 2018 Aug 17.

PMID:
29193883
48.

Addressing comorbidities in psoriatic disease.

Patel P, Rosen CF, Chandran V, Ye YJ, Gladman DD.

Rheumatol Int. 2018 Feb;38(2):219-227. doi: 10.1007/s00296-017-3895-y. Epub 2017 Nov 28.

PMID:
29185085
49.

Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis.

Abji F, Pollock RA, Liang K, Chandran V, Gladman DD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):486-489. Epub 2017 Nov 9.

PMID:
29148410
50.

More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2018 Jan;45(1):90-94. doi: 10.3899/jrheum.170645. Epub 2017 Nov 15.

PMID:
29142038

Supplemental Content

Loading ...
Support Center